A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

NCT07700745 | Active Not Recruiting

• 1 other identifier: REJUV-40748
• Study Type: interventional
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.

Conditions

Eczema; Atopic Dermatitis; Eczema-Prone Skin

Outcome Measures

Primary Outcomes (5)

• Change from Baseline in Self-Reported Skin Dryness

  Mean change in self-reported dryness measured via a structured self-report questionnaire administered through the Citruslabs platform

  Baseline to Week 4

• Change from Baseline in Self-Reported Skin Roughness

  Mean change in self-reported roughness measured via a structured self-report questionnaire administered through the Citruslabs platform

  Baseline to Week 4

• Change from Baseline in Self-Reported Skin Itch

  Mean change in self-reported itch measured via a structured self-report questionnaire administered through the Citruslabs platform

  Baseline to Week 4

• Change from Baseline in Self-Reported Skin Irritation

  Mean change in self-reported irritation measured via a structured self-report questionnaire administered through the Citruslabs platform

  Baseline to Week 4

• Change from Baseline in Self-Reported Skin Discomfort

  Mean change in self-reported discomfort measured via a structured self-report questionnaire administered through the Citruslabs platform

  Baseline to Week 4

Secondary Outcomes (4)

• Change from Baseline in Self-Reported Skin Hydration

  Baseline to Week 4

• Change from Baseline in Self-Reported Skin Comfort

  Baseline to Week 4

• Expert Dermatologist-Graded Change in Erythema

  Baseline and Week 4

• Expert Dermatologist-Graded Change in Scaling

  Baseline and Week 4

Study Arms (1)

Rejuvaskin Eczema Body Wash Arm

EXPERIMENTAL

Dietary Supplement: Rejuvaskin Eczema Body Wash

Interventions

Rejuvaskin Eczema Body Wash DIETARY_SUPPLEMENT

Participants use Rejuvaskin Eczema Body Wash once daily during a shower or bath in place of their usual body cleanser, followed by application of Rejuvaskin Skin Recovery Cream, for 4 consecutive weeks.

Rejuvaskin Eczema Body Wash Arm

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult women or men aged 18-65 years.
• Self-reported symptoms of eczema or eczema-prone skin (e.g., dryness, roughness, itching, irritation on the body).
• Visible signs of eczema such as dryness, roughness, or irritation on at least one part of the body at the time of enrollment.
• Willing to use Rejuvaskin Eczema Body Wash once daily as their primary body cleanser for 4 consecutive weeks.
• Willing to use Rejuvaskin Skin Recovery Cream once daily after using the - Rejuvaskin body cleanser for 4 consecutive weeks.
• Willing to maintain their current diet, skincare routine (aside from substitution of body wash and skin cream), and lifestyle habits for the study duration.
• Willing and able to take standardized photographs of an affected body area at Baseline and Week 4 using a personal smartphone.
• Able to read, understand, and complete questionnaires in English.
• Resides in the United States with a valid shipping address.
• Willing to provide informed consent and comply with all study procedures

You may not qualify if:

• Known allergy or sensitivity to any ingredient in the study product.
• Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
• Active, severe skin condition on the body requiring prescription topical or systemic treatment (e.g., active severe atopic dermatitis flare under medical care, active infection at intended application sites).
• Currently using prescription topical corticosteroids, calcineurin inhibitors, or other prescription topical eczema treatments on the body, or initiation of such treatment planned during the study.
• Currently participating in another clinical or skincare research study, or planning to enroll during this study's duration. (

Sponsors & Collaborators

• Rejuvaskin: lead
• Citruslabs: collaborator

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89118, United States

Location

MeSH Terms

Conditions

Eczema; Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2026
• First Posted: July 14, 2026
• Study Start: July 6, 2026
• Primary Completion: August 1, 2026
• Study Completion: August 1, 2026
• Last Updated: July 14, 2026

Record last verified: 2026-07

Locations

US (1)